RoSA Prostate Cancer Diagnostics Market to 2032
Overview
The RoSA Prostate Cancer Diagnostics Market is expected to reach a 195.44 USD Million by 2032 and is projected to grow at a CAGR of 15.41% from 2025 to 2032.
Revenue, 2024 (USD Million)
79.71
Forecast, 2032 (USD Million)
195.44
CAGR, 2024 - 2032
15.41%
Report Coverage
RoSA
RoSA Prostate Cancer Diagnostics Market 2018-2032 USD Million
RoSA Prostate Cancer Diagnostics Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 79.71 USD Million
- Projected Market Size (2032): 195.44 USD Million
- CAGR (2025-2032): 15.41%
Key Findings of RoSA Prostate Cancer Diagnostics Market
- The RoSA Prostate Cancer Diagnostics Market was valued at 79.71 USD Million in 2024.
- The RoSA Prostate Cancer Diagnostics Market is likely to grow at a CAGR of 15.41% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Prostatic Adenocarcinoma in Type Segment accounted for the largest share of the market with a revenue of 75.11 USD Million
- The fastest growing segment Castration-Resistant Prostate Cancer (Metastatic and Non-Metastatic) in Stage Segment grew Fastest with a CAGR of 17.35% during the forecast period from 2024 to 2032.
RoSA Prostate Cancer Diagnostics Market Scope
RoSA Prostate Cancer Diagnostics Market Segmentation & Scope
Diagnostics Type
- Confirmatory Tests
- Preliminary Screening Tests
Age Group
- Pediatric
- Adult
- Geriatrics
Type
- Others
- Small Cell Carcinoma
- Prostatic Adenocarcinoma
Stage
- Recurrent/Advanced Prostate Cancer
- Castration-Resistant Prostate Cancer (Metastatic and Non-Metastatic)
- Localized Prostate Cancer
Product Type
- Accessories
- Instruments
- Reagents & Consumables
Sample Type
- Others
- Urine
- Tissue
- Blood
End User
- Others
- Cancer Research Institutes
- Ambulatory Surgical Centers
- Clinics
- Hospitals
- Independent Diagnostic Laboratories
Distribution Channel
- Retail Sales
- Direct Tender
RoSA Prostate Cancer Diagnostics Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2022 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 79.71 USD Million |
| Market Value in 2032 | 195.44 USD Million |
| CAGR (2025-2032) | 15.41% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Diagnostics Type,Age Group,Type,Stage,Product Type,Sample Type,End User,Distribution Channel |
Regional Insights:
-
Leading Market (2024-2032): RoSA, leading in terms of revenue 79.71 USD Million in 2024
- Key Country: RoSA, leading in terms of revenue with value of 79.71 USD Million in 2024.
Segments and Scope
-
RoSA Prostate Cancer Diagnostics Market to 2032, By Diagnostics Type
- Preliminary Screening Tests is the largest segment in RoSA Prostate Cancer Diagnostics Market to 2032 with a revenue of 60.46 USD Million in the year 2024.
- Preliminary Screening Tests is the Fastest growing segment in RoSA Prostate Cancer Diagnostics Market to 2032 with a Growth rate of 16.02 % in forecast period 2025-2032.
-
RoSA Prostate Cancer Diagnostics Market to 2032, By Age Group
- Geriatrics is the largest segment in RoSA Prostate Cancer Diagnostics Market to 2032 with a revenue of 67.29 USD Million in the year 2024.
- Geriatrics is the Fastest growing segment in RoSA Prostate Cancer Diagnostics Market to 2032 with a Growth rate of 15.70 % in forecast period 2025-2032.
-
RoSA Prostate Cancer Diagnostics Market to 2032, By Type
- Prostatic Adenocarcinoma is the largest segment in RoSA Prostate Cancer Diagnostics Market to 2032 with a revenue of 75.11 USD Million in the year 2024.
- Prostatic Adenocarcinoma is the Fastest growing segment in RoSA Prostate Cancer Diagnostics Market to 2032 with a Growth rate of 15.53 % in forecast period 2025-2032.
-
RoSA Prostate Cancer Diagnostics Market to 2032, By Stage
- Localized Prostate Cancer is the largest segment in RoSA Prostate Cancer Diagnostics Market to 2032 with a revenue of 59.41 USD Million in the year 2024.
- Castration-Resistant Prostate Cancer (Metastatic and Non-Metastatic) is the Fastest growing segment in RoSA Prostate Cancer Diagnostics Market to 2032 with a Growth rate of 15.10 % in forecast period 2025-2032.
-
RoSA Prostate Cancer Diagnostics Market to 2032, By Product Type
- Reagents & Consumables is the largest segment in RoSA Prostate Cancer Diagnostics Market to 2032 with a revenue of 58.59 USD Million in the year 2024.
- Reagents & Consumables is the Fastest growing segment in RoSA Prostate Cancer Diagnostics Market to 2032 with a Growth rate of 15.99 % in forecast period 2025-2032.
-
RoSA Prostate Cancer Diagnostics Market to 2032, By Sample Type
- Blood is the largest segment in RoSA Prostate Cancer Diagnostics Market to 2032 with a revenue of 61.27 USD Million in the year 2024.
- Blood is the Fastest growing segment in RoSA Prostate Cancer Diagnostics Market to 2032 with a Growth rate of 15.80 % in forecast period 2025-2032.
-
RoSA Prostate Cancer Diagnostics Market to 2032, By End User
- Independent Diagnostic Laboratories is the largest segment in RoSA Prostate Cancer Diagnostics Market to 2032 with a revenue of 54.83 USD Million in the year 2024.
- Independent Diagnostic Laboratories is the Fastest growing segment in RoSA Prostate Cancer Diagnostics Market to 2032 with a Growth rate of 15.79 % in forecast period 2025-2032.
-
RoSA Prostate Cancer Diagnostics Market to 2032, By Distribution Channel
- Direct Tender is the largest segment in RoSA Prostate Cancer Diagnostics Market to 2032 with a revenue of 62.65 USD Million in the year 2024.
- Direct Tender is the Fastest growing segment in RoSA Prostate Cancer Diagnostics Market to 2032 with a Growth rate of 16.25 % in forecast period 2025-2032.
RoSA Prostate Cancer Diagnostics Market Company Share Analysis
| Company Name |
|
||
| Myriad Genetics, Inc. | |||
| OPKO Health, Inc. | |||
| Beckman Coulter, Inc. | |||
| Abbott | |||
| F. Hoffmann-La Roche Ltd. | |||
RoSA Prostate Cancer Diagnostics Market Geographical Sales Distribution, 2018-2032 USD Million
RoSA Prostate Cancer Diagnostics Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The RoSA Prostate Cancer Diagnostics Market is segmented based on Segmentation Diagnostics Type,Age Group,Type,Stage,Product Type,Sample Type,End User,Distribution Channel.
RoSA Prostate Cancer Diagnostics Market was valued at USD 79.71(Revenue in USD Million) in 2022.
RoSA Prostate Cancer Diagnostics Market is projected to grow at a CAGR of 15.41% during the forecast period of 2024 to 2032.
The Prostatic Adenocarcinoma segment is expected to dominate the RoSA Prostate Cancer Diagnostics Market, holding a largest market share of 75.11 USD Million in 2024
RoSA Prostate Cancer Diagnostics Market Scope
RoSA Prostate Cancer Diagnostics Market Segmentation & Scope
Diagnostics Type
- Confirmatory Tests
- Preliminary Screening Tests
Age Group
- Pediatric
- Adult
- Geriatrics
Type
- Others
- Small Cell Carcinoma
- Prostatic Adenocarcinoma
Stage
- Recurrent/Advanced Prostate Cancer
- Castration-Resistant Prostate Cancer (Metastatic and Non-Metastatic)
- Localized Prostate Cancer
Product Type
- Accessories
- Instruments
- Reagents & Consumables
Sample Type
- Others
- Urine
- Tissue
- Blood
End User
- Others
- Cancer Research Institutes
- Ambulatory Surgical Centers
- Clinics
- Hospitals
- Independent Diagnostic Laboratories
Distribution Channel
- Retail Sales
- Direct Tender
Frequently Asked Questions
The RoSA Prostate Cancer Diagnostics Market is segmented based on Segmentation Diagnostics Type,Age Group,Type,Stage,Product Type,Sample Type,End User,Distribution Channel.
RoSA Prostate Cancer Diagnostics Market was valued at USD 79.71(Revenue in USD Million) in 2022.
RoSA Prostate Cancer Diagnostics Market is projected to grow at a CAGR of 15.41% during the forecast period of 2024 to 2032.
The estimated market value of the RoSA Prostate Cancer Diagnostics Market for final year is USD 195.44 (USD Million).
RoSA Prostate Cancer Diagnostics Market Company Profiling
Frequently Asked Questions
The RoSA Prostate Cancer Diagnostics Market is segmented based on Segmentation Diagnostics Type,Age Group,Type,Stage,Product Type,Sample Type,End User,Distribution Channel.
RoSA Prostate Cancer Diagnostics Market was valued at USD 79.71(Revenue in USD Million) in 2022.
RoSA Prostate Cancer Diagnostics Market is projected to grow at a CAGR of 15.41% during the forecast period of 2024 to 2032.
The estimated market value of the RoSA Prostate Cancer Diagnostics Market for final year is USD 195.44 (USD Million).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.